Do analysts prefer SXTP or SLXN?

60 Degrees Pharmaceuticals currently has a consensus price target of $13.85, indicating a potential upside of 691.43%. Given 60 Degrees Pharmaceuticals' higher possible upside, equities analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than Silexion Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 60 Degrees Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Silexion Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor SXTP or SLXN?

In the previous week, Silexion Therapeutics had 1 more articles in the media than 60 Degrees Pharmaceuticals. MarketBeat recorded 4 mentions for Silexion Therapeutics and 3 mentions for 60 Degrees Pharmaceuticals. 60 Degrees Pharmaceuticals' average media sentiment score of 1.89 beat Silexion Therapeutics' score of 0.84 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 60 Degrees Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Silexion Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate SLXN or ENSC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silexion Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Ensysce Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer GOVX or SLXN?

GeoVax Labs presently has a consensus target price of $150.00, indicating a potential upside of 11,804.76%. Given GeoVax Labs' higher possible upside, research analysts clearly believe GeoVax Labs is more favorable than Silexion Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GeoVax Labs 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Silexion Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is GOVX or SLXN more profitable?

Silexion Therapeutics' return on equity of -516.86% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets GeoVax Labs N/A -709.52% -399.33% Silexion Therapeutics N/A -516.86% -176.68%

Does the media favor GOVX or SLXN?

In the previous week, GeoVax Labs had 1 more articles in the media than Silexion Therapeutics. MarketBeat recorded 5 mentions for GeoVax Labs and 4 mentions for Silexion Therapeutics. GeoVax Labs' average media sentiment score of 1.15 beat Silexion Therapeutics' score of 0.84 indicating that GeoVax Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GeoVax Labs 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Silexion Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend FLGC or SLXN?

Flora Growth currently has a consensus price target of $30.00, suggesting a potential upside of 900.00%. Given Flora Growth's higher possible upside, analysts clearly believe Flora Growth is more favorable than Silexion Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Flora Growth 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Silexion Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts rate SLXN or REVB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silexion Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Revelation Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, SLXN or REVB?

Silexion Therapeutics is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Silexion Therapeutics N/A N/A -$11.91M -$80.50 N/A Revelation Biosciences N/A N/A -$8.91M -$39.48 N/A

Is SLXN or REVB more profitable?

Revelation Biosciences' return on equity of -107.65% beat Silexion Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Silexion Therapeutics N/A -516.86% -176.68% Revelation Biosciences N/A -107.65% -87.98%

Silexion Therapeutics (SLXN) Competitors

$2.59 +0.04 (+1.57%)

Closing price 07/1/2026 04:00 PM Eastern

Extended Trading

$2.65 +0.06 (+2.32%)

As of 07/1/2026 07:59 PM Eastern

Compare

SLXN vs. SXTP, ENSC, GOVX, FLGC, and REVB

Should you buy Silexion Therapeutics stock or one of its competitors? MarketBeat compares Silexion Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Silexion Therapeutics include 60 Degrees Pharmaceuticals (SXTP), Ensysce Biosciences (ENSC), GeoVax Labs (GOVX), Flora Growth (FLGC), and Revelation Biosciences (REVB). These companies are all part of the "pharmaceutical products" industry.

How does Silexion Therapeutics compare to 60 Degrees Pharmaceuticals?

60 Degrees Pharmaceuticals (NASDAQ:SXTP) and Silexion Therapeutics (NASDAQ:SLXN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk.

60 Degrees Pharmaceuticals has higher revenue and earnings than Silexion Therapeutics. 60 Degrees Pharmaceuticals is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
60 Degrees Pharmaceuticals	$1.41M	3.30	-$7.36M	-$8.92	N/A
Silexion Therapeutics	N/A	N/A	-$11.91M	-$80.50	N/A

60 Degrees Pharmaceuticals currently has a consensus price target of $13.85, indicating a potential upside of 691.43%. Given 60 Degrees Pharmaceuticals' higher possible upside, equities analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than Silexion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
60 Degrees Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Silexion Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. Comparatively, 11.0% of Silexion Therapeutics shares are owned by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are owned by company insiders. Comparatively, 4.1% of Silexion Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Silexion Therapeutics has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -574.91%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Silexion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
60 Degrees Pharmaceuticals	-574.91%	N/A	-131.48%
Silexion Therapeutics	N/A	-516.86%	-176.68%

60 Degrees Pharmaceuticals has a beta of 2.46, indicating that its share price is 146% more volatile than the broader market. Comparatively, Silexion Therapeutics has a beta of -0.25, indicating that its share price is 125% less volatile than the broader market.

In the previous week, Silexion Therapeutics had 1 more articles in the media than 60 Degrees Pharmaceuticals. MarketBeat recorded 4 mentions for Silexion Therapeutics and 3 mentions for 60 Degrees Pharmaceuticals. 60 Degrees Pharmaceuticals' average media sentiment score of 1.89 beat Silexion Therapeutics' score of 0.84 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
60 Degrees Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Silexion Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

60 Degrees Pharmaceuticals beats Silexion Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Silexion Therapeutics compare to Ensysce Biosciences?

Silexion Therapeutics (NASDAQ:SLXN) and Ensysce Biosciences (NASDAQ:ENSC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Silexion Therapeutics has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -250.39%. Silexion Therapeutics' return on equity of -516.86% beat Ensysce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silexion Therapeutics	N/A	-516.86%	-176.68%
Ensysce Biosciences	-250.39%	-766.45%	-256.59%

In the previous week, Silexion Therapeutics had 2 more articles in the media than Ensysce Biosciences. MarketBeat recorded 4 mentions for Silexion Therapeutics and 2 mentions for Ensysce Biosciences. Silexion Therapeutics' average media sentiment score of 0.84 beat Ensysce Biosciences' score of 0.30 indicating that Silexion Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Silexion Therapeutics	Positive
Ensysce Biosciences	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silexion Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Ensysce Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

11.0% of Silexion Therapeutics shares are owned by institutional investors. Comparatively, 5.6% of Ensysce Biosciences shares are owned by institutional investors. 4.1% of Silexion Therapeutics shares are owned by insiders. Comparatively, 2.8% of Ensysce Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Ensysce Biosciences has higher revenue and earnings than Silexion Therapeutics. Ensysce Biosciences is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silexion Therapeutics	N/A	N/A	-$11.91M	-$80.50	N/A
Ensysce Biosciences	$5.07M	0.91	-$10.18M	-$3.35	N/A

Silexion Therapeutics has a beta of -0.25, indicating that its stock price is 125% less volatile than the broader market. Comparatively, Ensysce Biosciences has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market.

Summary

Silexion Therapeutics beats Ensysce Biosciences on 10 of the 14 factors compared between the two stocks.

How does Silexion Therapeutics compare to GeoVax Labs?

GeoVax Labs (NASDAQ:GOVX) and Silexion Therapeutics (NASDAQ:SLXN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership.

Silexion Therapeutics' return on equity of -516.86% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-709.52%	-399.33%
Silexion Therapeutics	N/A	-516.86%	-176.68%

In the previous week, GeoVax Labs had 1 more articles in the media than Silexion Therapeutics. MarketBeat recorded 5 mentions for GeoVax Labs and 4 mentions for Silexion Therapeutics. GeoVax Labs' average media sentiment score of 1.15 beat Silexion Therapeutics' score of 0.84 indicating that GeoVax Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GeoVax Labs	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Silexion Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Silexion Therapeutics has lower revenue, but higher earnings than GeoVax Labs. GeoVax Labs is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeoVax Labs	$2.49M	1.76	-$21.47M	-$19.12	N/A
Silexion Therapeutics	N/A	N/A	-$11.91M	-$80.50	N/A

6.1% of GeoVax Labs shares are owned by institutional investors. Comparatively, 11.0% of Silexion Therapeutics shares are owned by institutional investors. 0.7% of GeoVax Labs shares are owned by company insiders. Comparatively, 4.1% of Silexion Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

GeoVax Labs presently has a consensus target price of $150.00, indicating a potential upside of 11,804.76%. Given GeoVax Labs' higher possible upside, research analysts clearly believe GeoVax Labs is more favorable than Silexion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Silexion Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

GeoVax Labs has a beta of 3.68, meaning that its share price is 268% more volatile than the broader market. Comparatively, Silexion Therapeutics has a beta of -0.25, meaning that its share price is 125% less volatile than the broader market.

Summary

Silexion Therapeutics beats GeoVax Labs on 8 of the 14 factors compared between the two stocks.

How does Silexion Therapeutics compare to Flora Growth?

Flora Growth (NASDAQ:FLGC) and Silexion Therapeutics (NASDAQ:SLXN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings and risk.

In the previous week, Silexion Therapeutics had 4 more articles in the media than Flora Growth. MarketBeat recorded 4 mentions for Silexion Therapeutics and 0 mentions for Flora Growth. Silexion Therapeutics' average media sentiment score of 0.84 beat Flora Growth's score of 0.00 indicating that Silexion Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Flora Growth	Neutral
Silexion Therapeutics	Positive

36.0% of Flora Growth shares are owned by institutional investors. Comparatively, 11.0% of Silexion Therapeutics shares are owned by institutional investors. 2.3% of Flora Growth shares are owned by insiders. Comparatively, 4.1% of Silexion Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Silexion Therapeutics has a net margin of 0.00% compared to Flora Growth's net margin of -32.03%. Flora Growth's return on equity of -64.02% beat Silexion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Flora Growth	-32.03%	-64.02%	-34.46%
Silexion Therapeutics	N/A	-516.86%	-176.68%

Silexion Therapeutics has lower revenue, but higher earnings than Flora Growth. Flora Growth is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Flora Growth	$57.61M	0.05	-$15.91M	-$32.49	N/A
Silexion Therapeutics	N/A	N/A	-$11.91M	-$80.50	N/A

Flora Growth currently has a consensus price target of $30.00, suggesting a potential upside of 900.00%. Given Flora Growth's higher possible upside, analysts clearly believe Flora Growth is more favorable than Silexion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Flora Growth	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Silexion Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Flora Growth has a beta of 1.9, indicating that its share price is 90% more volatile than the broader market. Comparatively, Silexion Therapeutics has a beta of -0.25, indicating that its share price is 125% less volatile than the broader market.

Summary

Flora Growth beats Silexion Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Silexion Therapeutics compare to Revelation Biosciences?

Silexion Therapeutics (NASDAQ:SLXN) and Revelation Biosciences (NASDAQ:REVB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.

Silexion Therapeutics has a beta of -0.25, indicating that its share price is 125% less volatile than the broader market. Comparatively, Revelation Biosciences has a beta of -0.12, indicating that its share price is 112% less volatile than the broader market.

In the previous week, Silexion Therapeutics had 3 more articles in the media than Revelation Biosciences. MarketBeat recorded 4 mentions for Silexion Therapeutics and 1 mentions for Revelation Biosciences. Revelation Biosciences' average media sentiment score of 1.87 beat Silexion Therapeutics' score of 0.84 indicating that Revelation Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Silexion Therapeutics	Positive
Revelation Biosciences	Very Positive

Revelation Biosciences' return on equity of -107.65% beat Silexion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silexion Therapeutics	N/A	-516.86%	-176.68%
Revelation Biosciences	N/A	-107.65%	-87.98%

11.0% of Silexion Therapeutics shares are held by institutional investors. Comparatively, 12.8% of Revelation Biosciences shares are held by institutional investors. 4.1% of Silexion Therapeutics shares are held by company insiders. Comparatively, 4.8% of Revelation Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silexion Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Revelation Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Silexion Therapeutics is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silexion Therapeutics	N/A	N/A	-$11.91M	-$80.50	N/A
Revelation Biosciences	N/A	N/A	-$8.91M	-$39.48	N/A

Summary

Revelation Biosciences beats Silexion Therapeutics on 9 of the 12 factors compared between the two stocks.

Get Silexion Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLXN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLXN vs. The Competition

Export

Metric	Silexion Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.07M	$3.67B	$6.79B	$12.59B
Dividend Yield	N/A	2.21%	2.66%	6.15%
P/E Ratio	-0.03	21.28	27.41	25.27
Price / Sales	N/A	324.37	533.25	101.17
Price / Cash	N/A	141.54	47.99	59.26
Price / Book	0.31	8.71	10.96	6.62
Net Income	-$11.91M	$23.87M	$3.57B	$336.83M
7 Day Performance	-5.13%	4.34%	2.89%	3.19%
1 Month Performance	-48.10%	6.62%	3.70%	0.86%
1 Year Performance	-97.86%	61.64%	34.40%	27.51%

Silexion Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLXN Silexion Therapeutics	1.44 of 5 stars	$2.59 +1.6%	N/A	-97.8%	$1.07M	N/A	N/A	N/A	News Coverage
SXTP 60 Degrees Pharmaceuticals	3.5822 of 5 stars	$1.67 -0.6%	$13.85 +729.3%	-81.5%	$4.44M	$1.00M	N/A	3	News Coverage
ENSC Ensysce Biosciences	0.6902 of 5 stars	$0.29 +5.1%	N/A	-86.5%	$4.44M	N/A	N/A	10
GOVX GeoVax Labs	3.1326 of 5 stars	$1.26 -2.7%	$150.00 +11,852.2%	-89.6%	$4.36M	$2.49M	N/A	10	News Coverage Short Interest Decrease
FLGC Flora Growth	N/A	$4.04 +0.0%	$30.00 +642.6%	-87.2%	$4.23M	$57.61M	N/A	280

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLXN) was last updated on 7/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Silexion Therapeutics (SLXN) Competitors

SLXN vs. SXTP, ENSC, GOVX, FLGC, and REVB

How does Silexion Therapeutics compare to 60 Degrees Pharmaceuticals?

Summary

How does Silexion Therapeutics compare to Ensysce Biosciences?

Summary

How does Silexion Therapeutics compare to GeoVax Labs?

Summary

How does Silexion Therapeutics compare to Flora Growth?

Summary

How does Silexion Therapeutics compare to Revelation Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLXN vs. The Competition

Silexion Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Silexion Therapeutics (SLXN) Competitors

SLXN vs. SXTP, ENSC, GOVX, FLGC, and REVB

How does Silexion Therapeutics compare to 60 Degrees Pharmaceuticals?

Which has stronger valuation and earnings, SXTP or SLXN?

Do analysts prefer SXTP or SLXN?

Do insiders and institutionals believe in SXTP or SLXN?

Is SXTP or SLXN more profitable?

Which has more risk and volatility, SXTP or SLXN?

Does the media favor SXTP or SLXN?

Summary

How does Silexion Therapeutics compare to Ensysce Biosciences?

Is SLXN or ENSC more profitable?

Does the media prefer SLXN or ENSC?

Do analysts rate SLXN or ENSC?

Do institutionals and insiders hold more shares of SLXN or ENSC?

Which has stronger earnings and valuation, SLXN or ENSC?

Which has more risk & volatility, SLXN or ENSC?

Summary

How does Silexion Therapeutics compare to GeoVax Labs?

Is GOVX or SLXN more profitable?

Does the media favor GOVX or SLXN?

Which has stronger valuation & earnings, GOVX or SLXN?

Do institutionals and insiders have more ownership in GOVX or SLXN?

Do analysts prefer GOVX or SLXN?

Which has more volatility & risk, GOVX or SLXN?

Summary

How does Silexion Therapeutics compare to Flora Growth?

Does the media favor FLGC or SLXN?

Do institutionals and insiders hold more shares of FLGC or SLXN?

Is FLGC or SLXN more profitable?

Which has higher earnings & valuation, FLGC or SLXN?

Do analysts recommend FLGC or SLXN?

Which has more risk and volatility, FLGC or SLXN?

Summary

How does Silexion Therapeutics compare to Revelation Biosciences?

Which has more risk and volatility, SLXN or REVB?

Does the media refer more to SLXN or REVB?

Is SLXN or REVB more profitable?

Do institutionals & insiders believe in SLXN or REVB?

Do analysts rate SLXN or REVB?

Which has preferable valuation and earnings, SLXN or REVB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLXN vs. The Competition

Silexion Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools